Abstract: The invention provides a cell based method for the identification of Indoleamine 2,3-dioxygenase 1 (IDO1) and/or tryptophan 2,3-dioxygenase (TDO) modulators.
Abstract: The present invention is directed to compositions and methods for treating hepatitis B virus infection. In particular, the present invention is directed to a combination therapy comprising administration of an HBV capsid assembly inhibitor and an interferon for use in the treatment of hepatitis B virus infections.
Type:
Application
Filed:
May 3, 2018
Publication date:
September 6, 2018
Applicant:
Hoffmann-La Roche Inc.
Inventors:
Lu Gao, Isabel Najera, Hong Shen, Fang Shen, Liping Shi, Steffen Wildum, Guang Yang
Abstract: The present invention relates to compounds of formula (I), wherein R1 to R5 are as described herein, and their prodrugs or pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.
Abstract: The present invention relates to compounds that may be used for the treatment of Parkinson's disease, anxiety, emesis, obsessive compulsive disorder, autism, neuroprotection, cancer, depression and diabetes type 2. Compounds of formula I are representative, where substituents are defined herein: or a pharmaceutically acceptable salt or acid addition salt, a racemic mixture, or its corresponding enantiomer and/or optical isomer and/or stereoisomer thereof.
Type:
Grant
Filed:
September 18, 2017
Date of Patent:
September 4, 2018
Assignee:
Hoffmann-La Roche Inc.
Inventors:
Barbara Biemans, Wolfgang Guba, Georg Jaeschke, Jean-Marc Plancher, Antonio Ricci, Daniel Rueher, Eric Vieira, Fionn O'Hara
Abstract: The present invention relates to antibodies against human CSF-1R (anti-CSF-1R antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
Type:
Application
Filed:
January 19, 2018
Publication date:
August 30, 2018
Applicant:
HOFFMANN-LA ROCHE INC.
Inventors:
Nikolaos DIMOUDIS, Georg FERTIG, Alexander FIDLER, Klaus KALUZA, Marlene THOMAS, Carola RIES, Stefan SEEBER, Martin LANZENDOERFER (DECEASED)
Abstract: The invention relates to therapies for a patient with bleeding disorders, comprising the application of certain blood coagulation (clotting) factors in combination with antibodies.
Abstract: A device (1) for use in the detection of binding affinities comprises a planar waveguide (2) arranged on a substrate (22). The waveguide (2) has an outer surface (21) and a plurality of incoupling lines (31) for coupling a beam of coherent light into the waveguide (2) such that a parallel beam of coherent light (62) propagates along the waveguide (2). The incoupling lines (31) are curved and have an increasing distance between adjacent incoupling lines (31). A divergent beam of coherent light (61) of a predetermined wavelength is coupled into the waveguide (2) such that it propagates along the waveguide (2). A plurality of binding sites (51) is attached to the outer surface (21) along at least one further plurality of diffraction lines arranged in an outcoupling section of the waveguide (2). These diffraction lines comprise a plurality of curved outcoupling lines (41) having a decreasing distance between adjacent outcoupling lines.
Abstract: The invention relates to compounds which are mGlu2/3 negative allosteric modulators for use in the treatment of intellectual disabilities. In another aspect, the invention relates to a pharmaceutical composition for use in the treatment of intellectual disabilities comprising a compound according to the invention and a pharmaceutically acceptable carrier.
Type:
Application
Filed:
April 25, 2018
Publication date:
August 23, 2018
Applicant:
Hoffmann-La Roche Inc.
Inventors:
Theresa M. Ballard, Silvia Gatti McArthur, Michael Saxe, Juergen Wichmann, Thomas Woltering
Abstract: The present invention relates to compounds of formula hetaryl is a five membered heteroaryl group, containing 1 to 3 heteroatoms, selected from O, S or N; R1 is hydrogen, halogen, lower alkyl, lower alkoxy, lower alkyl substituted by halogen, S-lower alkyl substituted by halogen or lower alkoxy substituted by halogen, or two neighboring carbon atoms may form on phenyl an additional ring containing —O—CH2—O—; n is 1 to 5; R2 is hydrogen or lower alkyl substituted by halogen; R3 is hydrogen or lower alkyl substituted by halogen; or to pharmaceutically active acid addition salts thereof, to racemic mixtures or to its corresponding enantiomers or optical isomers or stereoisomers thereof. The compounds may be used for the treatment of Alzheimer's disease, cerebral amyloid angiopathy, hereditary cerebral hemorrhage with amyloidosis, Dutch-type (HCHWA-D), multi-infarct dementia, dementia pugilistica or Down syndrome.
Type:
Application
Filed:
March 6, 2018
Publication date:
August 23, 2018
Applicant:
Hoffmann-La Roche Inc.
Inventors:
Karlheinz Baumann, Guido Galley, Roland Jakob-Roetne, Anja Limberg, Werner Neidhart, Rosa Maria Rodriguez Sarmiento, Björn Bartels, Hasane Ratni
Abstract: The present invention relates to compounds of formula I wherein R1? is CH3 R1 is methyl, ethyl, CF3, CH2OH, cyclopropyl or cyano, or R1? and R1 may form together a 1,1-dioxo-tetrahydro-thiophen-3-yl ring; R2 is hydrogen, methyl, ethyl, isopropyl, tert-butyl, cyclopropyl, hydroxmethyl, or 2-propyl-2-ol; R3 is Cl, F, CF3, cyano, methyl, methoxy, isopropyl, or cyclopropyl; R4 is hydrogen, methyl, F or Cl; or to a pharmaceutically acceptable salt or acid addition salt, to a racemic mixture, or to its corresponding enantiomer and/or optical isomer and/or stereoisomer thereof. The compounds of formula I may be used in the treatment of psychiatric disorders such as schizophrenia, bipolar disorder, obsessive-compulsive disorder or autism spectrum disorder.
Abstract: Disclosed are compounds of Formula I, or pharmaceutically acceptable salts thereof, wherein W, X, Y, Z, R1, R2, R3, R4 and R5 are as described in this application, and methods of using said compounds in the treatment of cancer.
Type:
Grant
Filed:
November 14, 2014
Date of Patent:
August 21, 2018
Assignee:
Hoffmann-La Roche Inc.
Inventors:
Shaoqing Chen, Andrew F. Donnell, Robert Francis Kester, Kang Le, Yan Lou, Christophe Michoud, Stacy Remiszewski, Kenneth C. Rupert, Martin Weisel
Abstract: The current invention is directed to a chromatography column separator which separates the chromatography column in an upper chromatography column chamber and a lower chromatography column chamber, and which has a variable position within the chromatography column, and which is embedded by the chromatography material. The separator allows the replacement of the chromatography material in the upper chromatography column chamber without the need to replace the chromatography column material in the lower chromatography column chamber and it allows also the combination of two different chromatography materials with different chromatographical functional groups in one chromatography column.
Abstract: The invention provides novel compounds having the general formula: wherein R1 to R6, V, W, X and Y are as described herein, compositions including the compounds and methods of using the compounds.
Type:
Grant
Filed:
January 10, 2018
Date of Patent:
August 21, 2018
Assignee:
Hoffmann-La Roche Inc.
Inventors:
Xingchun Han, Min Jiang, Yongguang Wang, Song Yang
Abstract: The present invention relates to antibodies against human CD19 (anti-human CD19 antibodies), methods for their production, pharmaceutical compositions containing these antibodies, and methods of using the same.
Type:
Application
Filed:
March 30, 2018
Publication date:
August 16, 2018
Applicant:
Hoffmann-La Roche Inc.
Inventors:
Thomas HOFER, Claudia FERRARA KOLLER, Ekkehard MOESSNER, Mi HE
Abstract: Herein is reported a method for reducing the aggregation of an immunoglobulin in solution comprising the steps of i) comparing the amino acid sequence of the fourth framework region of the heavy chain of an antibody with a reference or germline sequence and determining whether one or more threonine residues and/or serine residues have been replaced by a different amino acid residue, and ii) modifying the amino acid sequence of the immunoglobulin by reverting the exchanged threonine residues and/or serine residues back to threonine or serine of the reference or germline sequence and thereby reducing the aggregation of an immunoglobulin in solution.
Type:
Grant
Filed:
August 21, 2015
Date of Patent:
August 14, 2018
Assignee:
HOFFMANN-LA ROCHE INC.
Inventors:
Hubert Kettenberger, Stefan Klostermann, Ulrich Kohnert, Sebastian Neumann
Abstract: The present invention provides a compound of formula (I) having BACE1 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of e.g. Alzheimer's disease.
Type:
Grant
Filed:
July 21, 2015
Date of Patent:
August 14, 2018
Assignee:
Hoffmann-La Roche Inc.
Inventors:
Bjoern Bartels, Cosimo Dolente, Wolfgang Guba, Wolfgang Haap, Andreas Kuglstatter, Ulrike Obst Sander, Jens-Uwe Peters, Mark Rogers-Evans, Thomas Woltering, Christian Schnider, Roger Wermuth
Abstract: The invention relates to a compound of formula (I) wherein R1 and R2 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.
Type:
Application
Filed:
April 4, 2018
Publication date:
August 9, 2018
Applicant:
Hoffmann-La Roche Inc.
Inventors:
Maude GIROUD, Wolfgang HAAP, Bernd KUHN, Rainer E. MARTIN
Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.
Type:
Application
Filed:
January 24, 2018
Publication date:
August 9, 2018
Applicant:
Hoffmann-La Roche Inc.
Inventors:
Oliver AST, Marina BACAC, Sabine IMHOF-JUNG, Christiane JAEGER, Christian KLEIN, Stefan KLOSTERMANN, Michael MOLHOJ, Joerg Thomas REGULA, Wolfgang SCHAEFER, Pablo UMANA
Abstract: Herein are provided bispecific anti-human CD20/human transferrin receptor antibodies and methods of using the same.
Type:
Application
Filed:
March 30, 2018
Publication date:
August 9, 2018
Applicant:
Hoffmann-La Roche Inc.
Inventors:
Harald DUERR, Sebastian FENN, Ulrich GOEPFERT, Sabine IMHOF-JUNG, Christian KLEIN, Laurent LARIVIERE, Michael MOLHOJ, Joerg Thomas REGULA, Petra RUEGER, Wolfgang SCHAEFER
Abstract: The present invention relates to methods that are useful for predicting the response of hepatitis B virus (HBV) infected patients to pharmacological treatment.
Type:
Application
Filed:
January 12, 2018
Publication date:
August 9, 2018
Applicant:
Hoffmann-La Roche Inc.
Inventors:
Lore Gruenbaum, Hua He, Vedran Pavlovic, Cynthia Wat